June 1st 2018

Press Release

Utrecht, the Netherlands – AQLANE Medical BV, is proud to announce that Urolon™, its bioresorbable urethral bulking agent, has received CE certification.

Results from our ongoing European clinical trial have shown Urolon™ be a safe and effective treatment option for women with mild to moderate SUI. The bioresorption profile, minimally-invasive and simple nature of the procedure make Urolon™ a very attractive and potentially first-line treatment option for mild to moderate SUI.

This milestone represents a platform for accessing the Urology, Urogynecology and Gynecology markets, supporting our claims by further expanding our clinical evidence database, and providing women access to an innovative treatment option for mild to moderate stress urinary incontinence (SUI). AQLANE Medical believes that Urolon™ can lead to a change in the treatment paradigm for SUI.

Additional regulatory approvals have been initiated to expand the AQLANE Medical's geographical reach.

About AQLANE Medical BV

AQLANE Medical™ is a privately owned medical device company based in Utrecht, The Netherlands, focused on the provision of novel bioresorbable medical solutions that are safe, effective and cost beneficial for the treatment of voiding dysfunctions. Our aim is to become a first choice for minimally invasive bioresorbable solutions for voiding dysfunctions. We operate based on our experience and expertise in the functionalization of bioresorbable polymers and gels in relation to desired device safety and efficacy performance characteristics.

For more information on AQLANE Medical™, please visit www.aqlanemedical.com, or send an email to info@alanemedical.com.

About Urolon™

Urolon™ is a non-pyrogenic, totally bioresorbable, non-permanent implant, whose principle component is synthetic polycaprolactone (PCL) microspheres suspended in an aqueous gel carrier. Urolon™ is injected sub-mucosally between the bladder neck and mid-urethra, creating increased tissue bulk and soft tissue augmentation of the urethra. The gel carrier suspends the PCL particles and allows delivery through injection needles and is dissipated in vivo, while the PCL particles remain at the injection sites and provide the tissue bulking to increase urethral resistance to urine leakage. Urolon™ is indicated for soft tissue augmentation in the treatment of stress urinary incontinence (SUI) in adult females.

For more information on Urolon™, please visit www.urolon.com.